Ask Mallard
Core concept

Choosing a master protocol

4 min read

Use basket and umbrella to describe the treatment-population structure; use platform to describe a trial that can evolve over time.

Fit

When it matters, and when it does not

It matters when

  • You must organize several linked treatment questions under one protocol.
  • You need to distinguish biomarker groups, diseases and changes to trial arms.

It matters less when

Before you start

What to check in your study

Decide these first
  1. Treatment and population structureState which treatments cross which diseases or biomarker groups.
  2. Arm changesDecide whether arms can enter, stop or replace others over time.
  3. Control strategySpecify randomization, concurrent controls and which groups may share information.
It rests on these
  1. Each comparison has a credible control and eligible population.How to check: Check calendar time, eligibility, standard care and overlapping control recruitment.
  2. Information sharing has a justified model.How to check: Test performance when effects differ across diseases or biomarker groups.
  3. Adaptation rules preserve the intended error control.How to check: Prespecify decisions and simulate plausible trial scenarios before recruitment.

Plain language

How it works

A basket design studies a treatment across disease groups linked by a shared feature. An umbrella design studies different treatments within one disease, often assigned by biomarkers. A platform can add or drop arms under standing rules. A platform may also have basket or umbrella features.

What decides the choice
Match the intended question to the approach. One treatment across disease groups leads to Basket: shared feature across diseases. Several treatments within one disease leads to Umbrella: biomarker-defined treatment groups. Arms may enter or stop over time leads to Platform: an evolving trial.Choose by the question and available structureOne treatment across disease groupsBasket: shared feature across diseasesSeveral treatments within one diseaseUmbrella: biomarker-defined treatmentgroupsArms may enter or stop over timePlatform: an evolving trialThese are choice criteria, not a ranking of evidence or a guarantee of validity.
Conceptual diagram. It shows the structure of the idea, not data from any study.
Controls and claims

Concurrent controls enroll while a treatment arm is open. Earlier controls are nonconcurrent; changes in care can bias the contrast. Shared controls make test results correlated. Define the family of claims and control false positives accordingly. A screening signal is not automatically confirmatory evidence. The single-design pages explain each trial structure.

Worked example

A worked example

Invented for illustration
Setting
A standing trial initially has four experimental arms.
Question
Does adding another arm change the protocol label?
Approach
The trial permits entry and stopping under prespecified rules. One arm stops and two arms enter.
Result
The active arm count changes from 4 to 5, a change of 1: 4 minus 1 plus 2 equals 5.
What it means
That evolution is a platform feature. Whether it is also basket or umbrella depends on its disease and treatment structure, not the arm count.

In practice

Recent studies PubMed search · not vetted

Searching PubMed…

Watch out

Common mistakes

The one to remember

Platform, basket and umbrella are overlapping descriptions, not guarantees of randomization or causal evidence. Shared controls, borrowing across groups and changing arms require prespecified validity and error-control rules.

  • Treating the three labels as mutually exclusive.Instead: Describe both population structure and evolution over time.
  • Assuming every master protocol randomizes.Instead: Read the allocation and control rules.
  • Sharing historical controls without checking time trends.Instead: Justify comparability and distinguish concurrent recruitment.
  • Calling a fixed shared-control test a platform engine.Instead: A Dunnett comparison addresses correlated tests against one control. It does not handle arm entry, stopping or changing care.

Inside Mallard

How Mallard uses this

Mallard includes this comparison in Learn search and the Atlas. Plans do not link to this comparison automatically.

No Mallard code example points to this page.
Atlas node concept.choosing_master_protocol_comparison, the id a plan cue records.

Related Learn pages

Related designs and methods

Evidence

Sources & further reading

  1. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both (opens in a new tab) · N Engl J Med · doi 10.1056/NEJMra1510062
  2. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (opens in a new tab) · N Engl J Med · doi 10.1056/NEJMoa1502309
  3. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer (opens in a new tab) · N Engl J Med · doi 10.1056/NEJMoa1513749
Prepared with AI assistance. PubMed records checked on 2026-11-06 for title, authors, year and DOI. The cited methods support the comparisons; record verification is not independent methodological approval.
Last source review: 2026-11-06
AI-generated educational content
Mallard uses reputable methodological and reporting sources, but this material may contain errors or omit important context. Verify important methodological decisions with the cited sources and, when appropriate, a qualified research methodologist or statistician.